David Anderson

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Antiretroviral Therapy

Randomized Controlled Trial

Top Venues

Journal of the International Association of Providers of AIDS Care

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

This page only lists publications with an associated author ORCID identifier.

Publications

David Anderson, Moti Ramgopal, Debbie P Hagins, Johnnie Lee, Richard Bruce Simonson, Tien-Huei Hsu, Ping Xu, Nina Ahmad, William R Short
DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Keith Dunn, Bryan Baugh, Nika Bejou, Donghan Luo, Jennifer Campbell, Sareh Seyedkazemi, David Anderson
Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. Journal of the International Association of Providers of AIDS Care 21 (2022)
Keith Dunn, Jennifer Bushen, Donghan Luo, Jiyun Cai, Richard Bruce Simonson, David Anderson
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis. HIV medicine 24 (3) (2022)
Keith Dunn, Jennifer Bushen, Donghan Luo, Jiyun Cai, Richard Bruce Simonson, David Anderson
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis. HIV medicine 24 (3) (2022)
Keith Dunn, Jennifer Bushen, Donghan Luo, Jiyun Cai, Richard Bruce Simonson, David Anderson
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis. HIV medicine 24 (3) (2022)
Keith Dunn, Jennifer Bushen, Donghan Luo, Jiyun Cai, Richard Bruce Simonson, David Anderson
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis. HIV medicine 24 (3) (2022)